Weekly Investment Analysts’ Ratings Updates for Eli Lilly and (LLY)

Eli Lilly and (NYSE: LLY) recently received a number of ratings updates from brokerages and research firms:

  • 2/2/2018 – Eli Lilly and had its “hold” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $80.00 price target on the stock.
  • 2/1/2018 – Eli Lilly and had its price target lowered by analysts at Bank of America Corp from $88.00 to $86.00. They now have a “neutral” rating on the stock.
  • 2/1/2018 – Eli Lilly and had its price target raised by analysts at BMO Capital Markets from $73.00 to $74.00. They now have an “underperform” rating on the stock.
  • 1/22/2018 – Eli Lilly and was downgraded by analysts at Credit Suisse Group AG from a “neutral” rating to an “underperform” rating. They now have a $82.00 price target on the stock.
  • 1/16/2018 – Eli Lilly and was given a new $100.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 1/16/2018 – Eli Lilly and was downgraded by analysts at Goldman Sachs Group Inc from a “buy” rating to a “neutral” rating. They now have a $95.00 price target on the stock, up previously from $86.98.
  • 1/5/2018 – Eli Lilly and was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $115.00 price target on the stock, up previously from $85.52.

Eli Lilly and Co (LLY) traded up $0.14 during midday trading on Monday, reaching $76.37. The company’s stock had a trading volume of 2,341,002 shares, compared to its average volume of 5,300,003. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The firm has a market cap of $83,940.00, a PE ratio of -381.85, a price-to-earnings-growth ratio of 1.39 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. During the same quarter in the previous year, the firm posted $0.95 EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. research analysts predict that Eli Lilly and Co will post 4.88 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.95%. Eli Lilly and’s payout ratio is presently -1,040.00%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold a total of 259,610 shares of company stock worth $22,727,406 in the last quarter. 0.20% of the stock is currently owned by insiders.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply